Abstracts

CyTOF-Lec REVEALS GLYCAN FEATURES DEFINING CELLS DIFFERENTIALLY SUSCEPTIBLE TO HIV

High-parameter single-cell phenotyping has enabled in-depth classification and interrogation of immune cells, but to date has not allowed for cell-surface glycan characterization. To simultaneously characterize glycans + proteins at the single-cell level, we modified our recently established CyTOF panels. The resulting CyTOF-Lec panel was developed by conjugating lectins (glycan-binding proteins with known specificity) to metal…

MONOMERIC HIV-1 ENVELOPE CYTOPLASMIC TAILS ARE SUFFICIENT FOR Gag LATTICE RETENTION

To combat the prevalence of Human Immunodeficiency Virus-1 (HIV-1) and emerging antiviral resistance, new antiviral classes must be pursued. An attractive target for new classes includes the virus assembly process. To create an infectious particle, the structural Gag polypeptide coalesces into a lattice on the plasma membrane of an infected cell. Coincidently, viral envelope glycoproteins…

RAPALOGS DOWNMODULATE INTRINSIC IMMUNITY AND PROMOTE CELL ENTRY OF SARS-CoV-2

SARS-CoV-2 infection in immunocompromised individuals has been associated with prolonged virus shedding and the development of novel viral variants. Rapamycin and rapamycin analogs (rapalogs, including everolimus, temsirolimus, and ridaforolimus) are FDA-approved for use as mTOR inhibitors in multiple clinical settings, including cancer and autoimmunity, but a common side effect of these drugs is immunosuppression and…

IFITM DEPENDENCY OF SARS-CoV-2 VARIANTS OF CONCERN

We recently showed that genuine SARS-CoV-2 hijacks endogenously expressed interferon-induced transmembrane proteins, especially IFITM2, as entry cofactors for efficient infection (Prelli Bozzo, Nchioua et al., Nat. Com., 2021). This came as a surprise, since IFITMs have been reported to inhibit entry of numerous enveloped viruses, including SARS-CoV-2. However, most data were obtained using IFITM overexpression…

INTERFERON RESISTANCE OF EMERGING SARS-CoV-2 VARIANTS

The continuing spread of SARS-CoV-2 provides opportunities for the virus to evolve. Compared to ancestral strains, the 4 major variants of concern (VOC) exhibit Spike mutations that improve entry and/or diminish antibody neutralization. However, mutations have arisen in other viral genes. Several of these genes may counteract innate immunity mediated by antiviral interferons (IFNs). IFNs…

TYPE-I INTERFERON MODULATION IN VIVO BLOCKS SARS-CoV-2 REPLICATION AND INFLAMMATION

Systemic and local inflammation following SARS-CoV-2 infection has been widely described and predictive of disease severity and death. However, the exact immune mediators driving inflammation contributing to SARS-CoV-2 host defense vs. those driving immune-mediated pathology in humans have not been fully elucidated. Deficiencies in type-I interferon (IFN-I) responses, including inborn errors to genes in the…

SARS-CoV-2 SPIKE BINDS FIBRINOGEN-INDUCING ABNORMAL INFLAMMATORY BLOOD CLOTS

Life threatening thrombotic events involving both the arterial and venous systems are prominently present in SARS-CoV-2 infected individuals presenting with severe COVID-19. Abnormal clotting also occurs in asymptomatically or mildly infected individuals and in people experiencing post-acute sequelae of SARS-CoV-2 infection (PASC). Clinical management of this clotting disorder has proven difficult in part because these…

UNIVERSAL HEPATITIS C VIRUS SCREENING IN PREGNANCY: THE JUICE IS WORTH THE SQUEEZE

Recently, the American College of Obstetrics and Gynecology joined the CDC in recommending universal hepatitis C virus (HCV) screening of pregnant people. Universal HCV screening is hypothesized to increase the detection of HCV among pregnant people, resulting in fewer undetected perinatal HCV transmissions. Screening and case detection of HCV during risk-based vs. universal HCV screening…